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Identifying diagnostic DNA methylation profiles
for facioscapulohumeral muscular dystrophy in
blood and saliva using bisulfite sequencing
Takako I Jones1*, Chi Yan1,2, Peter C Sapp3, Diane McKenna-Yasek3, Peter B Kang4, Colin Quinn3,5, Johnny S Salameh3,
Oliver D King1,3,6 and Peter L Jones1,3,6*
Abstract
Background: Facioscapulohumeral muscular dystrophy (FSHD) is linked to chromatin relaxation due to epigenetic
changes at the 4q35 D4Z4 macrosatellite array. Molecular diagnostic criteria for FSHD are complex and involve analysis
of high molecular weight (HMW) genomic DNA isolated from lymphocytes, followed by multiple restriction digestions,
pulse-field gel electrophoresis (PFGE), and Southern blotting. A subject is genetically diagnosed as FSHD1 if one of
the 4q alleles shows a contraction in the D4Z4 array to below 11 repeats, while maintaining at least 1 repeat, and
the contraction is in cis with a disease-permissive A-type subtelomere. FSHD2 is contraction-independent and
cannot be diagnosed or excluded by this common genetic diagnostic procedure. However, FSHD1 and FSHD2 are
linked by epigenetic deregulation, assayed as DNA hypomethylation, of the D4Z4 array on FSHD-permissive alleles.
We have developed a PCR-based assay that identifies the epigenetic signature for both types of FSHD, distinguishing
FSHD1 from FSHD2, and can be performed on genomic DNA isolated from blood, saliva, or cultured cells.
Results: Samples were obtained from healthy controls or patients clinically diagnosed with FSHD, and include both
FSHD1 and FSHD2. The genomic DNAs were subjected to bisulfite sequencing analysis for the distal 4q D4Z4 repeat
with an A-type subtelomere and the DUX4 5’ promoter region. We compared genomic DNA isolated from saliva and
blood from the same individuals and found similar epigenetic signatures. DNA hypomethylation was restricted to the
contracted 4qA chromosome in FSHD1 patients while healthy control subjects were hypermethylated. Candidates
for FSHD2 showed extreme DNA hypomethylation on the 4qA DUX4 gene body as well as all analyzed DUX4 5’
sequences. Importantly, our assay does not amplify the D4Z4 arrays with non-permissive B-type subtelomeres and
accurately excludes the arrays with non-permissive A-type subtelomeres.
Conclusions: We have developed an assay to identify changes in DNA methylation on the pathogenic distal 4q
D4Z4 repeat. We show that the DNA methylation profile of saliva reflects FSHD status. This assay can distinguish
FSHD from healthy controls, differentiate FSHD1 from FSHD2, does not require HMW genomic DNA or PFGE, and
can be performed on either cultured cells, tissue, blood, or saliva samples.
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Background
Facioscapulohumeral muscular dystrophy (FSHD) is the
most prevalent myopathy that indiscriminately affects
males and females of all ages [1-3]. Although clinical
muscle weakness typically manifests in the second or
third decade of life, there is great variability in clinical
severity, from a severe infantile form to individuals who
remain asymptomatic throughout their lives [1,2,4-7].
Genetically, there are two classes of FSHD that are both
linked to the chromosome 4q35 D4Z4 macrosatellite
array (Figure 1). In the healthy population, these poly-
morphic regions exist as 11 or more repeat units (RUs)
on each chromosome (24 to 35 RUs on average and up
to ~120 [8]). A patient is genetically diagnosed with
FSHD1 if pulse-field gel electrophoresis (PFGE) analysis
indicates that one of the 4q alleles has a contraction in
the D4Z4 array to below 11 RUs, while maintaining at
least 1 RU, and the contraction is in cis with a FSHD-
permissive 4A-type subtelomere containing a functional
polyadenylation signal (PAS) for the pathogenic DUX4-fl
(DUX4-full length) mRNA [9-15]. In contrast, the far
less common form, FSHD2, is highly similar to FSHD1
in clinical presentation, yet it is contraction-independent
and cannot be diagnosed or excluded by this common
molecular diagnostic procedure [16,17]. However, as
with FSHD1, FSHD2 also requires a disease-permissive
4A-type subtelomere allele distal to the D4Z4 array on
at least one 4q chromosome [15], suggesting the expres-
sion of DUX4-fl is likely a key mechanism in both forms
of FSHD. Interestingly, the majority of 4A-type subtelo-
meres are, in fact, disease-permissive [15,18]. FSHD1
and FSHD2 are also linked by epigenetic deregulation,
typically assayed by DNA methylation analysis, of the
4qA FSHD-permissive allele [17,19]. In healthy subjects,
both copies of the 4q35 D4Z4 array as well as both
copies of the 10q26 D4Z4 array have hypermethylated
DNA (>35% CpGs assayed are methylated). In FSHD1
patients, the contracted 4q35 D4Z4 array exhibits DNA
hypomethylation while the non-contracted 4q35 allele
remains hypermethylated [17,19,20]. FSHD2 patients do
not have contractions in either 4q35 array; however,
both 4q35 D4Z4 arrays and both 10q26 D4Z4 arrays are
severely hypomethylated (<25% CpGs assayed are meth-
ylated) due to mutations in the SMCHD1 (structural
maintenance of chromosomes flexible hinge domain con-
taining1) gene, or other yet-to-be-identified epigenetic
modifiers of D4Z4 repression [17,19,21]. These DNA
hypomethylation signatures are specific to FSHD, as DNA
methylation patterns of the 4q/10q D4Z4 arrays in other
muscular dystrophies are similar to those found in healthy
subjects [17].
The typical genetic diagnosis for FSHD1 is complex
[12,22]. It first requires careful isolation of 40 to 50 μg
of very high molecular weight (HMW) DNA from
peripheral blood mononuclear cells (PBMCs) obtained
from fresh blood samples [18]. The purified genomic
DNA is then embedded in agarose for in-gel digestion
with combinations of several restriction enzymes. The
agarose-DNA plugs are subjected to PFGE, Southern
blotting, and hybridizations with DNA probes: the p13E-
11 probe to identify the size of each 4q35 and 10q26
array [23], and probes for the generally permissive A-type
subtelomere and the non-permissive B-type subtelomere
to identify the haplotype of 4q35 and 10q26 chromo-
somes, respectively. Recently, an alternative fluorescent
cell-based technique, termed molecular combing, was
developed to identify an FSHD1 deletion on a 4qA
chromosome [24]. The additional information one obtains
from these assays includes interchromosomal rearrange-
ments and potential somatic mosaicism; however, these
assays are incapable of identifying a functional DUX4-fl
PAS [12,22,25,26]. The ~5% of clinical FSHD patients that
do not have an FSHD1-sized pathogenic 4qA allele are
candidates for FSHD2, but neither assay can identify these
individuals as FSHD2 as opposed to another myopathy
with similar clinical symptoms. Sequencing the SMCHD1
gene for known FSHD2 mutations in candidates with
permissive 4A-type subtelomeres will identify many, but
not all, FSHD2 subjects [21,27,28].
Here, we designed a new analytical method to address
several issues critical to FSHD clinicians and researchers.
We first sought to develop a molecular assay that could
readily distinguish FSHD2 from FSHD1 and other limb-
girdle-like myopathies. Ideally, the assay would not
require isolation of HMW DNA and could be performed
from saliva samples for sampling convenience. Since the
majority of 4A subtelomeres are disease permissive in all
forms of FSHD [15,18], and distinct 4q and 10q D4Z4
hypomethylation profiles are characteristic for FSHD1
and FSHD2, we have developed an assay using a set of
three PCR-based bisulfite sequencing (BSS) reactions
that together identify the epigenetic signatures for FSHD1,
FSHD2, and unaffected subjects. Our D4Z4 BSS analysis
can clearly distinguish each form of FSHD from the others
by assessing the overall DNA methylation status of both
4q35 D4Z4 arrays, providing a precise DNA methylation
pattern for the distal-most D4Z4 repeat on the contracted
allele, and having specificity for the generally permissive
4A subtelomere (Figure 2). Furthermore, this analysis does
not require HMW DNA or any special equipment and
can be performed on as little as 1 μg of genomic DNA
isolated from blood, tissue, or saliva, using standard
molecular biology techniques. Importantly, we show
that the DNA methylation profiles of the 4q35 D4Z4 in
saliva yield comparable results to those in blood. Although
we used traditional subcloning and Sanger sequencing for
proof-of-principle, our method can easily be modified for
high-throughput acquisition and analysis using bar-coded
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oligonucleotides and next-generation sequencing methods.
This method will identify characteristic FSHD epigenetic
signatures in cis with a 4A subtelomere, distinguish FSHD2
from FSHD1 subjects, and enable epigenetic studies on
the FSHD pathogenic locus. In addition, although it does
not provide the size of a D4Z4 contraction or identify
functional PAS, this method, when used as a diagnostic
tool with patients that exhibit a clinical manifestation of
neuromuscular disease, will likely out-perform current
PFGE or molecular combing diagnostics by not only
accurately characterizing patients with short D4Z4 arrays
on permissive 4qA chromosomes as having FSHD1, but
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Figure 1 The molecular signatures of FSHD are complex, as illustrated by healthy and FSHD-type chromosomes. In the general healthy
population, each chromosome 4q arm has a large polymorphic array of D4Z4 repeats containing more than 10 RUs. In FSHD1, there is a dominant
contraction of one 4q array to between 1 and 10 D4Z4 repeat units, whereas FSHD2 is contraction-independent. There are two main allelic variants in
the subtelomere distal to the array, termed A and B. A rare third classification of subtelomere, termed C, is used for subtelomeres that do not hybridize
with probes for A or B due to distal sequence changes [18]. In some instances, the distal-most repeat fragment of the 4q D4Z4 array contains add-
itional ~2 kb of D4Z4 sequence, resulting in a longer terminal RU in cis with a 4qA subtelomere; this type of 4qA allele is referred to as 4qA-L [15]. Both
FSHD1 and FSHD2 are exclusively linked to the 4qA subtelomere allelic variants containing a PAS for the DUX4-fl mRNA [12,15]. In addition, both FSHD1
and FSHD2 require the epigenetic disruption of the D4Z4 array to a less methylated and more relaxed chromatin state. Results of the described
bisulfite sequencing assays are indicated by “+” if a bisulfite (BS) PCR product is produced and “–” if no BS PCR product is produced. *On rare
occasions, due to primer degradation, a 10qA BS PCR product is detected; however, sequencing eliminates these from analysis. **Diagnosis of
this healthy chromosome requires genomic PCR and sequencing of the 4qA subtelomere to identify a non-permissive 4qA PAS.
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also accurately preventing many patients with contracted
arrays on non-permissive chromosomes from being mis-
diagnosed as FSHD1.
Results and discussion
Development of a combined distal 4qA-specific and
4q/10q 5’ D4Z4 DNA methylation assay
Dramatic epigenetic differences at the 4q35 D4Z4 repeat
array between healthy and disease states distinguish FSHD1
and FSHD2 from unaffected individuals. Epigenetic differ-
ences at the non-contracted 4q35 D4Z4 and the 10q26
D4Z4 arrays distinguish FSHD2 from FSHD1 and other
myopathies. In all forms of FSHD, it is the distal 4q35
D4Z4 in cis with a disease-permissive 4A subtelomere that
produces the pathogenic DUX4-fl mRNA [15]. However,
this pathogenic D4Z4 repeat has never been specifically
analyzed in FSHD1 or FSHD2 [17,19,20,29]. Therefore, in
order to study epigenetic changes at the disease-relevant
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Figure 2 Schematic for bisulfite sequencing (BSS) analysis of FSHD-associated 4qA chromosomes and 4q D4Z4 repeat units. (A) Cartoon
depicting the location of bisulfite (BS) PCR products for the 4qA BSS assay (blue), the 4qA-L BSS assay (orange), and the DUX4 5’ BSS assay (green). For
the DUX4 5’ reaction, the nested primer has a preference for a 4q D4Z4 polymorphism (red “x”); however, a fraction of D4Z4 units are amplified from
chromosome 10q arrays (denoted by thin green lines), (*) including chromosome 4q-type D4Z4 units present on chromosome 10q due to trans
chromosomal rearrangements found in ~6% of subjects [18]. The proximal BsaAI and FseI methylation-sensitive restriction enzyme sites analyzed by
Southern blotting are indicated (B and F, respectively) and highlighted in yellow. (B and C) Diagrams of the distal-most D4Z4 repeat that produces the
polyadenylated DUX4-fl mRNA and is analyzed in the (B) 4qA BSS assay and (C) 4qA-L BSS assay. Arrows indicate BS PCR primers and red “X” indicates
sequence differences with 4qA; rare 10A or 4A166 products amplified in the absence of 4A alleles and due to primer degradation are detected and
eliminated from analysis by specific sequence polymorphisms (Additional file 1: Figure S1). Neither 4qA nor 4qA-L BSS assay amplifies the 4qB allelic variant.
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D4Z4 repeat, we developed two BSS assays that specific-
ally analyze the distal 4qA- or 4qA-L-associated D4Z4 RU
(Figure 2). Utilizing polymorphisms in the BSS PCR
primers that are exclusive to the disease-permissive 4A
subtelomere and not found in 10A, the 4qA BSS assay an-
alyzes the DNA methylation status of 56 CpGs (Additional
file 1: Figure S1A) in the distal D4Z4 RU in cis with a 4A
subtelomere (Figure 2B). The 4qA bisulfite (BS)-PCR
product is amplified from all BS-converted genomic
DNAs from subjects possessing at least one 4qA allele
(Figure 3, upper panel). The D4Z4-4A fragments were
sequenced and, importantly, all 56 CpGs predicted by the
reference sequence were accounted for in >90% of the
analyzed sequences from these clones, confirming the
specificity of the reaction for the distal 4qA-derived
D4Z4. The 4qA-L BSS assay utilizes the same 4A
subtelomere-specific reverse BS PCR primers as above;
however, these are paired with a 4qA-L-specific forward
BS PCR primer. The 4qA-L BSS assay analyzes the DNA
methylation status of 30 CpGs (Additional file 1: Figure
S1D) in the distal D4Z4 repeat on 4qA-L chromosomes
(Figure 2C). The 4qA-L BS PCR product was amplified
exclusively from BS-converted genomic DNAs from the
one subject possessing a 4qA-L allele and not from any of
the six subjects lacking a 4qA-L allele (Figure 3, middle
panel). The 4qA-L fragment was sequenced and all 30
CpGs predicted by the reference sequence were accounted
for in 100% of the analyzed sequences from these clones,
confirming the specificity of the reaction for the distal
4qA-L-derived D4Z4. Neither the 4qA BS PCR nor the
4qA-L BS PCR produced a product from genomic DNAs
isolated from either of the two healthy subjects with 4qB/
B haplotypes. It is worth noting that due to the 4qA-
specific SNPs residing at the 3’ end of the 4qA BS PCR
oligonucleotide primers, multiple rounds of primer freeze-
thaw, which leads to partial primer degradation, results in
a loss of specificity and a consequent amplification of
minor products from genomic DNAs lacking the 4qA
allele (Additional file 1: Figure S1B). Sequence analysis of
these rare amplicons from 4qB/B samples identified them
as either a 10qA product (Additional file 1: Figure S1C)
or a non-specific product not derived from any D4Z4
or 4qA/B allelic variant. In addition, since the BSS
analysis is sequence-based and not product-based (as in
qPCR or Southern blotting), any rare non-specific or
10qA amplifications present are easily identified and
removed from the analysis. We conclude that these
assay conditions amplify the distal D4Z4 sequence from
4qA chromosomes or 4qA-L chromosomes, depending
on the assay, and neither assay amplifies 10A or 4B
subtelomere-containing chromosomes.
To complement the distal D4Z4 methylation analysis
and provide the context for both 4q35 D4Z4 arrays that
is important for the determination of FSHD2 status, we
designed a third BSS analysis upstream of the DUX4
open reading frame (referred to as the DUX4 5’ BSS
assay). This assay analyzes the methylation status of 59
CpGs preferentially in 4q35 D4Z4 RUs but also in 10q35
D4Z4 RUs (Figures 2 and Additional file 1: Figure S1E).
This DUX4 5’ region can be amplified from all 4q35 and
10q26 D4Z4 RUs, does not amplify homologous D4Z4s
elsewhere in the genome [30], and encompasses a putative
CTCF binding site and the DR1 region found to be hypo-
methylated in all 4q and 10q D4Z4 RUs in FSHD2 cells
[29,31]. As anticipated, all seven of the BS-converted
genomic DNAs were successfully amplified using this
protocol (Figure 3, lower panel), validating the integrity of
the BS-converted DNAs from the two healthy subjects.
Analysis of the DUX4 5’ BSS products revealed that all 59
of the CpGs predicted by the reference sequence were
accounted for in all sequences in this assay, confirming
that these sequences were derived from 4q/10q D4Z4
RUs, which characteristically have very few polymor-
phisms, and not from homologous D4Z4s located
Figure 3 Bisulfite (BS) PCRs using genomic DNAs from subjects with a range of 4q allelic combinations show the specificity of the three
bisulfite sequencing (BSS) assays. Nested PCRs were performed using BS-converted genomic DNAs from seven subjects, five FSHD1 and two
healthy, with varying 4q haplotypes (4qA/A, 4qA/B, 4qB/B, and 4qA/A-L, as indicated). The primer sets used are indicated to the right of each panel.
The 4qA BS PCR (upper panel) amplified a product from all five subjects possessing at least 1 4qA allele and did not amplify any detectable product
from the two subjects lacking a 4qA allele. The 4qA-L BS PCR (middle panel) only amplified a product from the one subject possessing a 4qA-L allele.
The DUX4 5’ BS PCR (lower panel) amplified a product from all seven subjects. The identities of all BS PCR products were confirmed by sequencing.
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elsewhere in the genome that contain numerous sequence
polymorphisms [30]. Thus, combining the DUX4 5’ BSS
and 4qA/4qA-L BSS assays provides a detailed analysis of
the DNA methylation status of the pathogenic distal 4qA
D4Z4 RU in the context of overall 4q/10q D4Z4 DNA
methylation.
Characterization of healthy and FSHD1 DNA methylation
patterns in the distal D4Z4 repeat unit using blood and
saliva
Epigenetic marks often show tissue specificity; thus, it is
very important to carefully examine and compare each
locus of interest when performing epigenetic studies on
genomic DNAs isolated from different tissue sources [32].
Since FSHD is a myopathy and the pathogenic DUX4
mRNA is expressed predominantly in skeletal muscle
[1,33], the epigenetic status of myocytes is of particular
interest. However, muscle biopsies require participants to
visit a hospital or clinic, and can be expensive, painful, and
difficult to obtain from FSHD patients of any age already
exhibiting muscle atrophy. Fortunately, in FSHD1 and
FSHD2, the DNA methylation status of the 4q35 D4Z4 is
similar between PBMCs and myogenic cells [17]. For
example, in FSHD1, the proximal repeats of the D4Z4
array on the contracted 4q35 allele are significantly hypo-
methylated in both PBMCs and myogenic cells compared
to the non-contracted allele or healthy controls [17]. In
order to assess the DNA methylation status of the
pathogenic distal 4q35 D4Z4 repeat, we used our 4qA
and 4qA-L BSS assays to analyze the distal D4Z4 in
PBMCs from FSHD1 patients and healthy first-degree
relatives. In addition, we are interested in analyzing the
epigenetic signatures of large numbers of family members
over time, including healthy individuals, some of whom
may be identified as potential asymptomatic carriers.
Therefore, in addition to testing our assay on genomic
DNA isolated from PBMCs, we performed our analysis
on saliva samples obtained from the same subjects for a
comparison. The advantage of saliva samples is that
they can be collected without additional help, there is
no needle injection, and collection kits can be mailed
to subjects who have undergone informed consent, with
the stable 2 mL sample returned by standard mail. This
type of testing would be particularly useful for children
and in communities or countries where access to a
phlebotomist is limiting or relatively expensive and/or
standard genetic testing by PFGE or molecular combing
is cost-prohibitive or unavailable.
A blind comparison of DNA methylation profiles using
the three BSS protocols was performed on genomic
DNAs isolated from blood and saliva from two clinically
diagnosed and genetically confirmed FSHD1 subjects and
two healthy first-degree relatives (Figure 4). The assays
analyzed all 56 CpGs in the distal D4Z4 of each 4qA array,
all 30 CpGs in the distal D4Z4 of 4qA-L linked arrays,
when present, and 59 CpGs in the DUX4 5’ region of all
samples, as described above (Figure 2). All FSHD subjects
will possess at least one 4qA (or 4qA-L) allele, and non-
FSHD control subjects have either two, one, or no 4qA
(or 4qA-L) alleles. Healthy control subjects with either
one or two 4qA/4qA-L alleles are predicted to show DNA
hypermethylation (>35% methylation) on all assayed
chromosomes, whereas those with 4qB/B genotypes will
not produce a BS PCR product or in some rare instances
produce a 10qA product that is effectively removed from
analysis by identifying sequence polymorphisms. FSHD1
subjects must have at least one 4qA allele in cis with a
contracted D4Z4. In FSHD1 subjects with 4qA/B hap-
lotypes, all of the analyzed chromosomes are derived
from the contracted D4Z4 array and are expected to
show hypomethylation. In FSHD1 subjects with 4qA/A
or 4qA-L/A-L haplotypes, on average half of the analyzed
chromosomes will be derived from the contracted array
and are expected to show DNA hypomethylation while
the other half will be derived from the non-contracted
array and are expected to show hypermethylation. In
subjects with 4qA/A-L haplotypes, all of the BSS clones
in each assay will be derived from the same chromosome,
either contracted or non-contracted.
To avoid diluting the signature of FSHD1 by averaging
with the methylation levels of the non-contracted array,
we use the first quartile (Q1) of the methylation percent
of all analyzed chromosomes as a summary statistic.
This corresponds to dividing all sequences into two
groups based on methylation percentage, and taking the
median value of only those sequences in the lower
group. If the total number of sequences is odd, there is
the issue of whether to include the central sequence in
the lower group or not before taking the median; to give
it half weight we compute the median both ways, then
take the arithmetic average. This corresponds to the R
function quantiles with type = 5.
In a 4qA/A FSHD1 subject for whom all chromosomes
with the contracted array have lower 4qA BSS methylation
than any chromosomes with the non-contracted array, Q1
gives an estimate of the median 4qA methylation of just
the contracted array. With n = 10 sequences analyzed,
there is a 5.4% chance that more than 75% will arise from
the non-contracted allele due to random sampling, so Q1
will not be an accurate reflection of the contracted allele;
increasing n to 18 reduces the probability of this sort of
failure to 1.5%.
Note, however, that if there is any overlap in methylation
levels between alleles (as may be expected in healthy con-
trols, FSHD2 subjects, and, potentially, in some FSHD1
subjects as well), then the half of analyzed sequences with
lower methylation need not arise from a single allele, and
Q1 underestimates the median methylation of any one
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allele. In the extreme case of no difference in methylation
distributions between two 4qA alleles, or of 4qA/4qB
genotypes (in which all sequences arise from a single
allele), Q1 instead is an estimate of the lower quartile
of methylation of one allele, rather than the median.
This bias is tolerable for the present application, so for
simplicity we use Q1 (Additional file 2: Table S1) as a
summary statistic uniformly for all samples, without
requiring the genotype to be known; we have also
developed a mixture-model based statistical approach
that aims to mitigate this bias [unpublished observations
by Jones et al. 2014].
As shown in Figure 4A and Additional file 2: Table S1,
the distal 4qA D4Z4 was dramatically hypomethylated
Figure 4 BSS analysis identifies distinct epigenetic signatures for FSHD1 and healthy controls that are similar between genomic DNA
samples isolated from blood and saliva. Genomic DNAs isolated from PBMCs or saliva from the same four subjects were analyzed using the
(A) 4qA BSS assay and 4qA-L BSS assay, and (B) the DUX4 5’ assay. Expected CpGs, based on predicted sequence composition of the unconverted
region amplified, are listed in numerical order. Red boxes indicate methylated CpGs, blue boxes indicate unmethylated CpGs, and white boxes
indicate no CpG at the expected site. The DNA methylation for the Q1 is indicated along with the range from the lowest percentage methylation
to the highest percentage methylation in the set. *Neither the 4qA BS PCR nor the 4qA-L BS PCR produced a product from this subject, indicating that
no 4qA or 4qA-L alleles were present; therefore, an alternative BSS protocol (4q/10q BSS) that amplifies both 4qA and 10qA alleles was performed
(see Methods). The white boxes indicate no CpGs were detected at positions #16 and #55, which suggested these sequences were derived from 10qA.
However, analysis of the complete BSS sequence data provided an additional non-CpG polymorphism that identified all sequences as being
derived from 4C166H chromosomes.
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in both blood and saliva samples for subjects 75194
(Q1 = 21.4% methylated, PBMCs; Q1 = 10.7% methyl-
ated, saliva) and 75204 (Q1 = 7.1% methylated, PBMCs;
Q1 = 8.9% methylated, saliva), and was hypermethylated
in both blood and saliva of subject 75195 (Q1 = 87.5%
methylated, PBMCs; Q1 = 89.3% methylated, saliva). The
4qA-L BSS analysis indicated that the A-L haplotype was
only present in subject 75194 and this allele was hyper-
methylated (Q1 = 70.8% methylated, PBMCs; Q1 = 80.0%
methylated, saliva). Neither of these 4qA-specific BS PCRs
produced a product from either the PBMCs or saliva of
subject 75205, indicating that this subject lacked any 4qA
alleles. Based on this analysis we predicted that subjects
75194 and 75204 were FSHD patients, and subjects 75195
and 75205 were healthy controls.
To further investigate the BSS results, we performed a
second BS PCR on DNAs from subjects 75204 and
75205 utilizing a BS PCR primer set (primers BSS1438F
and BSS3702R) that amplifies the distal D4Z4 region
from both 4qA and 10qA for nested PCR (Figure 5A).
The BSS profile of the 75205 products from both saliva
and PBMCs showed no 4qA or 4qA-L chromosomes and
suggested amplification of 10qA (Figure 4, 4A/10A row),
as indicated by the lack of CpGs #16 and #55 (typically a
10A166 haplotype BSS signature). However, analysis of
the entire amplified sequence revealed a polymorphism in
all products that, when combined with the methyl-CpG
profile, corresponded to the non-permissive 4C166H
haplotype [18]. To confirm the haplotypes predicted by
the BSS, genomic PCR was performed on all DNA
samples to detect the presence of 4qA, 4qA-L, and 4qB
subtelomeres (Figure 5B), as described [15]. As suggested
by the BSS results in Figure 4A, subjects 75194, 75195,
and 75204 all contained at least one 4qA allele and subject
75194 also contained one 4qA-L allele. Subjects 75204
and 75205 each tested positive for a 4qB allele. Interest-
ingly, subject 75205 also tested positive for a 4qA allele
from both PBMC and saliva DNAs despite producing
no 4qA BS PCR product (Figure 5B), indicating that this
4qA haplotyping PCR also amplifies 4qC chromosomes.
Sequence analysis of the genomic PCR products confirmed
that subject 75205 has one chromosome with a 4C166H
haplotype, consistent with the BSS data (Figure 4A), further
supporting the specificity of the 4qA BSS assay. This more
complete analysis supports our initial conclusions and
provides additional information as follows: subjects 75194
(4qA/A-L) and 75204 (4qA/B) were FSHD patients and
subjects 75195 (4qA/A) and 75205 (4qB/4C166H) were
healthy controls.
BSS analysis of the DUX4 5’ promoter region is more
complex (Figure 2). This analysis was designed to prefer-
entially detect all 4q D4Z4s regardless of haplotype from
both the contracted and non-contracted 4q chromosome
arrays. Because in FSHD1 only the contracted chromosome
4 D4Z4 is hypomethylated [17], the observed proportion
of hypomethylated sequences is expected to depend on
the number of D4Z4 RUs in the contracted 4q array rela-
tive to the number of D4Z4 RUs on the non-contracted
4q array, together with chromosome 4q-type RUs on
hybrid chromosome 10s, if present. In addition, preference
for the 4q D4Z4 is based on a conserved 4q-specific poly-
morphism at the 3’ terminal base of a BSS PCR primer;
however, since this relies on a single base polymorphism,
there is the potential that a fraction of 10q-derived D4Z4
sequences could be amplified. In fact, sequence analysis of
the DUX4 5’ BS PCR products identified both 4qA-
specific polymorphisms and 10q-specific polymorphisms,
indicating that although the reaction has a preference for
4q, it does not preclude amplification of some 10q array
RUs. Fortunately, this does not adversely affect our
analysis. For healthy controls, we anticipate that the
vast majority of the analyzed chromosomes will show
D4Z4 hypermethylation (>35% methylation) regardless
of origin. By contrast, FSHD1 subjects should contain a
combination of hypermethylated (from D4Z4 RUs resid-
ing in the non-contracted 4q array and both 10q arrays)
and hypomethylated (from the D4Z4 RUs residing in the
contracted 4q array) sequences with a clear minority of
the analyzed D4Z4 RUs being hypomethylated; FSHD2
subjects should be hypomethylated (~ <25% methylation)
Figure 5 PCR haplotyping. (A) BS PCR products for subjects 75204 and 75205 using the 4qA DUX4 gene body primer set (left) or a primer set
that non-specifically amplifies both 4qA and 10qA. BL: blood (PBMCs) and SA: saliva. (B) Genomic PCR amplification for either the 4qA or 4qB
subtelomeres [15], as indicated. Although the 4qA D4Z4 gene body BS PCR did not produce a product for subject 75205 (No), standard PCR for
4qA alleles did produce a PCR product. These products were sequenced and confirmed as being 4C166H. These data together indicate that
subject 75205 has a 4qB/C166H genotype. Additional predicted genotypes are indicated.
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on most sequences analyzed. Thus, the DUX4 5’ BSS assay
is expected to be less sensitive than the 4qA and 4qA-L
BSS assays in distinguishing FSHD1 from healthy controls;
however, this assay should support those results, and
would clearly distinguish FSHD2 from FSHD1 or healthy
controls. Therefore, to more accurately distinguish FSHD1
from FSHD2 we use the mean percent methylation of
each sample for comparison (Additional file 2: Table S1).
The DUX4 5’ BSS analysis was tested on the same eight
genomic DNA samples as above (Figure 4B). As with the
4qA BSS assay, DUX4 5’ BS products from subjects 75195
(91.0% methylation mean, PBMCs; 94.4% methylation
mean, saliva) and 75205 (71% methylation mean, PBMCs;
63.9% methylation mean, saliva) showed pronounced
DNA hypermethylation in both PBMCs and saliva,
suggesting that these two subjects were healthy controls.
Subjects 75194 (47.8% methylation mean, PBMCs; 59.7%
methylation mean, saliva) and 75204 (50.8% methylation
mean, PBMCs; 59.3% methylation mean, saliva) showed
less methylation than the putative controls but more
methylation, on average, than found for these samples in
the 4qA BSS analysis. However, in accordance with our
predictions for FSHD1, these subjects contained a mixture
of hypermethylated and hypomethylated DNA, resulting
in a wide range of DNA methylation density per analyzed
chromosome that reached much lower in subjects 75194
(5.1 to 78.0% methylation, PBMCs; 5.1 to 81.4% methyla-
tion, saliva) and 75204 (6.8 to 91.5% methylation, PBMCs;
5.1 to 88.1% methylation, saliva) compared with 75195
(72.9 to 100% methylation, PBMCs; 78.0 to 100% methy-
lation, saliva) and 75205 (40.7 to 88.1% methylation,
PBMCs; 32.2 to 86.4% methylation, saliva). This data indi-
cates that subjects 75194 and 75204 are FSHD1 and not
FSHD2 patients, while subjects 75195 and 75205 are
healthy controls. In each case, the genomic DNAs isolated
from PBMCs and saliva samples produced similar BSS
results for each subject.
Upon final analysis, subjects 75194 and 75204 exhibited
D4Z4 hypomethylation detected by the 4qA BSS analysis
(Q1 < 25% methylated), indicative of FSHD, and by the
DUX4 5’ BSS analysis they were clearly not FSHD2 (see
below) and were thus predicted to be two FSHD1 patients.
In fact, subjects 75194 and 75204 indeed had positive
genetic tests for FSHD1. Importantly, subject 75204
(34 kb EcoRI/BlnI fragment corresponding to 9 D4Z4
RUs) and subject 75194 (27 kb EcoRI/BlnI fragment
corresponding to 7 D4Z4 RUs) were both in the high
end of the genetic FSHD1 contraction range, yet both
were still accurately identified as FSHD1 by our analysis
highlighting the sensitivity of these assays. Similarly,
subjects 75195 and 75205, displaying hypermethylation at
D4Z4 of all analyzed sequences by both the 4qA BSS and
the DUX4 5’ BSS methods, were accurately determined to
be healthy controls. With respect to the distal 4qA BSS
analysis, subject 75195 was accurately identified from both
blood and saliva genomic DNA as a healthy control, while
control subject 75205 was accurately determined to lack a
4qA allele at either chromosome 4 (see below).
Overall, genomic DNAs isolated from blood and saliva
provided similar epigenetic profiles of the FSHD-associated
D4Z4 array in FSHD1 affected patients and healthy first-
degree relatives. This test analysis confirmed the specificity
of the 4qA BSS and 4qA-L BSS protocols for 4qA alleles
over 10qA alleles or 4qB alleles. In addition, we have
applied this analysis to myogenic cells or PBMCs from
an additional 20 subjects having a clinical and genetic
diagnosis of FSHD1 and 10 subjects confirmed as healthy
unaffected. The simple cutoff of Q1 < 30% for 4qA and
4qA-L methylation accurately classified 19 of the 20 FSHD
subjects and 9 of the 10 healthy controls (P = 7 × 10-6
by Fisher’s Exact Test); the one false positive was the
only sample in the intermediate zone of 25% <Q1 < 35%
[unpublished observations by Jones et al., 2014]. We con-
clude that the described BSS analysis can readily identify
FSHD1 hypomethylation, is suitable for epigenetic analysis
of the D4Z4 array in both FSHD1 and healthy subjects,
and that saliva samples are comparable to PBMCs in
terms of providing suitable genomic DNA for DNA
methylation analysis of the 4q35 D4Z4.
Identification of the FSHD2 DNA hypomethylation signature
Current genetic testing for FSHD, either by PGFE or
molecular combing, detects a contracted 4qA D4Z4 array
(FSHD1) and produces a negative result in ~5% of clinic-
ally diagnosed FSHD cases. These subjects are candidates
for FSHD2. FSHD2 can be diagnosed in two ways:
genomic sequencing of the SMCHD1 gene for a known
(or likely) FSHD2 mutation (valid for ~85% of cases)
or epigenetic analysis of the D4Z4 array (valid for
100% of known cases). The distinguishing feature of
FSHD2 is DNA hypomethylation (<25% methylation)
of both the 4q35 and 10q26 D4Z4 arrays [19,21]. In
addition, as is the case with FSHD1, FSHD2 requires at
least one permissive 4qA allele. Since our BSS analysis
identifies 4qA haplotypes and determines the DNA
methylation profiles of the D4Z4 arrays on both 4q
chromosomes, we sought to determine if our method
could be used to identify cases of FSHD2. We used gen-
omic DNAs isolated from fibroblasts or blood obtained
from a family containing three known FSHD2 subjects
possessing a mutation in SMCHD1 and two unaffected
relatives (Figure 6) [27]. Our BSS analysis of the DUX4 5’
region showed extreme DNA hypomethylation (3.2%,
18.5%, and 11.5% methylation means) in all three FSHD2
subjects and, conversely, DNA hypermethylation (49.9%
and 59.3% methylation means) of both healthy controls
(Figure 6B, right column). The 4qA BSS analysis positively
detected at least one 4qA allele in each FSHD2 subject
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with concurrent DNA hypomethylation of all analyzed
sequences, and healthy controls were hypermethylated
on all 4qA chromosomes (Figure 6B, left column). These
DNA methylation profiles are strikingly distinct from
those found for FSHD1 (Figure 4) and clearly identify
these subjects as FSHD2. We conclude that our BSS assay
can be used to positively detect an FSHD2 epigenetic
signature with a permissive 4A subtelomere, readily dis-
tinguishable from that of FSHD1 or healthy controls,
using standard genomic DNA preparations from multiple
sources.
We further tested the utility of this assay by analyzing
PBMC genomic DNA isolated from a subject (RB19518)
who was clinically diagnosed with FSHD but had a
negative genetic test result for FSHD1 by the standard
PFGE technique. FSHD2 is characterized by <25% methy-
lation of all four 4q and 10q D4Z4 arrays. In less than
five days following retrieval of genomic DNA, the results
of our FSHD BSS assays showed a 15.5% methylation
mean in the DUX4 5’ region, with a range of 5.1 to 22%
methylation, and a Q1 = 7.1% methylation using the 4qA
BSS assay, with a range of 5.4 to 14.3% methylation,
indicating that all detected D4Z4s were hypomethylated
(Figure 6B, lower panels). This analysis indicated that
this subject had a clear FSHD2 epigenetic signature and a
likely permissive 4A subtelomere and thus, when com-
bined with the clinical evaluation, is very likely FSHD2.
We conclude that this assay is a quick and efficient way
to determine FSHD2 epigenetic signatures and does not
require HMW DNA.
Figure 6 BSS analysis of genomic DNA samples distinguishes FSHD2 from FSHD1. (A) Partial pedigree for family 1090, which has a known
FSHD2 mutation in the SMCHD1 gene that segregates with disease [27]. (B) The 4qA BSS analysis (left) and DUX4 5’ BSS analysis (right) for genomic
DNAs isolated from subjects in family 1090 or subject RB19518, as indicated. Genomic DNAs were isolated from fibroblasts for subject 1090-1 and
PBMCs for all other subjects. Expected CpGs, based on predicted sequence composition of the unconverted region amplified, are listed in numerical
order. Red boxes indicate methylated CpGs, blue boxes indicate unmethylated CpGs, and white boxes indicate no CpG detected at the expected site.
The Q1 percent methylation is indicated for the 4qA BSS assays and the mean percent methylation is indicated for the DUX4 5’ BSS assays.
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Identification and elimination of the rare 10A176T and
4A166 non-permissive haplotypes from BSS analysis
It is important to keep in mind that the majority of ana-
lyzed chromosomes in FSHD and healthy subjects will
have chromosomes with standard 4qA (44%, including
4qA-L), 4qB (50%), and 10qA (91%) haplotypes; however,
there are some important exceptions to consider [18].
Two of them are the rare, non-permissive 10A176T and
4A166 haplotypes, neither of which is identified by
current standard diagnostic testing [18]. Since D4Z4
arrays of 10A176T have chromosome 4-like resistance
to digestion with Bln-I, the enzyme used to distinguish
chromosome 4 arrays from chromosome 10 arrays, this
chromosome 10 haplotype can be misidentified as chro-
mosome 4 by PFGE analysis and 4A166 linked arrays are
indistinguishable from permissive 4qA arrays using PFGE.
Thus, the presence of 10A176T or 4A166 can complicate
genetic diagnosis and epigenetic analyses, particularly
when these haplotypes are associated with a short D4Z4
array. Since the prevalence of 10A176T and 4A166 in the
European population are ~2.5% and ~4.1%, respectively, it
is to be expected that ~1 out of 15 FSHD patients, healthy
control subjects, and even patients with other myopathies
will carry one of these potentially confusing haplotypes
[18]. Fortunately, the 10A176T and 4A166 alleles have
several distinguishing polymorphisms and can be identi-
fied by PCR haplotyping of genomic DNA [15]. However,
for our diagnostic purposes as well as epigenetic analyses,
it is important to know if our 4qA and 4qA-L BSS assays
can identify and/or eliminate these non-permissive
10A176T or 4A166 haplotypes from the BSS analysis.
Therefore, we tested our 4qA and 4qA-L BSS assays
on genomic DNAs known to contain the 10A176T allele.
We identified two subjects (27A and 27B) from the same
family who have very short D4Z4 arrays in cis with the
10A176T haplotype and lacking a permissive 4qA allele
[6]. As shown (Figure 7A, upper panel), no BS PCR
product was amplified from these subjects using these
assays. This was not surprising considering both 4A166
and 10A176T share the same sequence polymorphisms
in the primer BSS3626R that was used to eliminate BS
PCR product amplification from non-permissive 10qA
(Additional file 1: Figure S1). To confirm the content
and integrity of these BS-converted DNAs, we used an
alternative BSS primer that is not predicted to distin-
guish 4A from 10A176T for amplification (Figure 7A,
lower panel). Analysis of the amplified product revealed
that all sequences matched the predicted polymorphisms
for 10A176T, and not 4A or 10A, including the lack of
CpG #55 but not CpG #16 (Figure 7B). Therefore, this
additional BSS assay can be used to both positively iden-
tify and study the methylation status of chromosomes
with the 10A176T haplotype. We conclude that the 4qA
and 4qA-L BSS assays do not amplify the 10A176T or
4A166 haplotypes and effectively eliminate them from
the methylation analysis.
Combined analysis and epigenetic diagnosis of FSHD
The three BSS assays presented use DNA methylation
levels of the terminal D4Z4 RU to distinguish FSHD from
healthy unaffected subjects as well as FSHD1 from FSHD2
(Figure 8). However, in describing the BSS methods here,
only two FSHD1 subjects, four FSHD2 subjects, and four
unaffected control subjects were used for this proof-of-
principle analysis (Figures 4 and 6). To confirm that the
epigenetic signatures of the distal 4qA and DUX4 5’
regions could truly be used in the diagnosis of FSHD, we
analyzed data produced from our much more extensive
epigenetic study of FSHD1-affected and FSHD1-non-
manifesting subjects, which applied this protocol to a
Figure 7 The 4qA BSS analysis does not amplify from 10A176T or 4A166 alleles. (A) The 4qA BSS assay (upper panel) is specific for 4qA
sequences (present in sample 17A) and does not amplify the non-permissive 10A176T or 4A166 alleles present in samples 27A and 27B. BSS
PCR using oligonucleotide primers that do not distinguish between 4A and 10A176T (lower panel) amplifies robustly from all three samples.
(B) Sequence analysis of the products from samples 27A and 27B confirmed their origins as being from a 10A176T allele. The lack of a detectable CpG
at position #55 but the presence of a CpG at position #16 identifies these as derived from a chromosome with a 10A176T haplotype. Expected CpGs,
based on predicted sequence composition of the unconverted region amplified, are listed in numerical order. Red boxes indicate methylated CpGs,
blue boxes indicate unmethylated CpGs, and white boxes indicate no CpG detected at the expected site.
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larger number of samples [unpublished observations by
Jones et al., 2014]. PBMCs or myogenic cells from a total
of 20 clinically affected FSHD1 and 10 healthy subjects,
all confirmed by PFGE as FSHD1 or unaffected, were
analyzed. The FSHD1 contractions ranged from 14 to
32 kb EcoRI/BlnI fragments in cis with a permissive A
subtelomere, while the shortest 4qA allele EcoRI/BlnI
fragment from all unaffected healthy controls was >53 kb.
Our analysis of DNA methylation using the 4qA BSS assay
with cutoff of Q1 < 30% accurately classified 19 of the 20
FSHD subjects and 9 of the 10 healthy controls. Interest-
ingly, our previous analysis of DUX4 expression showed
that myogenic cells from the false positive, sample 16U,
express DUX4-fl mRNA and protein [6], consistent with
our epigenetic analysis. This is in stark contrast to the
recent BSS method for FSHD published by Gaillard et al.
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Bisulfite Conversion
4qA BS PCR
Methylation >35%
  4qA AND 4qA-L
No BS PCR Product
        No 4qA and 
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Figure 8 Flow chart of epigenetic diagnosis of FSHD1 and FSHD2 by BSS. Clinical samples, including saliva, blood, muscle tissue, or cells, from
patients with a clinical diagnosis of neuromuscular disease consistent with FSHD can be used for genomic DNA isolation and an epigenetic diagnosis
of FSHD1 or FSHD2. The first level BSS assays, namely the 4qA and 4qA-L BSS assays, identify FSHD. The second level assay, namely the DUX4
5’ assay, distinguishes between FSHD1 and FSHD2. *Sequence analysis can be performed by subcloning and Sanger sequencing of a minimum of 10
independent clones; alternatively, a NGS approach can be used. Sequences are screened for 10A, 10A176T, and 4A166 and, if present, those sequences
are removed from the analysis. The lower quartile (Q1) of the percent methylation is computed for the remaining sequences, to improve sensitivity for
detecting hypomethylation on a contracted allele when roughly half the sequences are from a non-contracted allele and are hypermethylated. **If no
BS PCR product is generated then the subject likely lacks a permissive 4A haplotype. Genomic PCRs for A- and B-type subtelomeres and sequencing
can be used to confirm the results. ***Sequence analysis of the BS PCR product, which is derived from both 4q and 10q arrays and thus present in all
samples, can be performed by subcloning and Sanger sequencing of a minimum of 10 independent clones; alternatively, a NGS approach can be used.
The mean DNA methylation of 10 sequences is not expected to identify strong changes in FSHD1 patients since the vast majority of sequences are
likely derived from either the non-contracted 4q or either of the 10q D4Z4 arrays; however, FSHD2 shows hypomethylation (<25% methylation mean)
on both 4q and both 10q D4Z4 arrays. Precise cutoffs may need to be adjusted as more samples are examined.
Jones et al. Clinical Epigenetics 2014, 6:23 Page 12 of 16
http://www.clinicalepigeneticsjournal.com/content/6/1/23
[34], which reported significant population differences
between FSHD1 and healthy subjects, but has limited
diagnostic benefit on an individual basis. This is not
surprising considering the authors use an approach that
assays all D4Z4 repeat units from chromosome 4 and
chromosome 10 (and perhaps other D4Z4 repeats as
well, given the large number of polymorphisms observed
in CpG sites [30]), since sequences from the contracted 4q
allele then make a small and highly variable contribution
to the overall average methylation level. Methylation levels
for control samples showed a coefficient of variation (SD/
mean) of ~15% in Figure 5C (left) by Gaillard et al. [34];
thus if only ~10% of sequences in an FSHD1 sample are
derived from the contracted allele (as would be expected
with, for example, 5 D4Z4 RU on the contracted 4q allele
and 45 D4Z4 RU on the non-contracted 4q allele, a
conservative estimate as it ignores D4Z4 repeats on
other chromosomes), their impact on the observed aver-
age methylation level is less than the normal variation
between control subjects.
Even a small false positive rate (e.g., 1%) can result in
poor positive predictive value when applied to populations
in which FSHD prevalence is smaller still (such as the
general population). However, since individuals with a
variety of non-FSHD muscular dystrophies have D4Z4
methylation-levels similar to healthy controls [17], our
assay can be used as a differential diagnostic between
FSHD and other diseases when applied to patients with
clinical characteristics consistent with FSHD. In addition,
all of the samples from FSHD1 subjects that were tested
with the DUX4 5’ BSS assay showed DNA methylation
levels above 25%, consistent with an FSHD1 diagnosis and
not FSHD2. Conversely, all FSHD2 subjects showed DNA
methylation levels well below 25% in both the DUX4 5’
and 4qA BSS assays, providing clear evidence for FSHD2
as opposed to FSHD1. However, while this assay is specific
for the generally FSHD permissive 4qA allele, as with
standard FSHD1 testing by PFGE or molecular combing
[24], it does not positively identify a functional DUX4
PAS, which is required of a truly permissive 4qA allele.
We conclude that the combination of these two assays
used for individuals with clinical symptoms of FSHD is
diagnostic for FSHD1 and FSHD2 (Figure 6).
Conclusions
We have developed a PCR-based technique to identify
and distinguish all forms of FSHD from DNA methy-
lation profiles in blood, saliva, or fibroblasts. The com-
bination of two BSS assays allows the analysis of the
DNA methylation profile of a portion of the distal 4q35
D4Z4 RU associated with all forms of FSHD. These
assays are specific for 4q chromosomes with the FSHD-
associated A-type subtelomere and do not amplify D4Z4
sequence from B-type subtelomeres. Sequences from
non-permissive 10qA (including 10qA176T) and 4A166
are not amplified in most assays and, if present (a sign
of PCR primer degradation), are readily removed from
analysis. The DNA methylation profiles produced by
this assay clearly distinguish between FSHD and healthy
subjects (Figure 8). We also describe a companion BSS
assay that analyzes the DNA methylation status of a
region 5’ of the DUX4 gene that is present on all 4q35
and 10q26 D4Z4 repeats. Utilizing the three BSS assays
in combination discloses the DNA methylation status
of the distal D4Z4 in the context of overall 4q35 D4Z4
DNA methylation. Therefore, in addition to determining
contracted 4qA-specific DNA hypomethylation charac-
teristic of FSHD1 and overall D4Z4 hypermethylation
in healthy controls, this assay identifies FSHD2-specific
DNA hypomethylation signatures on the 4qA allele
and clearly distinguishes them from FSHD1 signatures
(Figure 8). Importantly, this analysis does not require
HMW genomic DNA and can be performed on genomic
DNAs isolated from blood or saliva, producing similar
results. Additionally, the protocols can readily be modified
with bar-coded oligonucleotide primers such that data
acquisition and analysis can be performed using next-
generation sequencing technology.
Methods
Subjects and methods
The University of Massachusetts Medical School Institu-
tional Review Board approved this study; participants
provided written informed consent. Patients 75194, 75204,
and RB19518 were clinically diagnosed as FSHD. Patients
75194 and 75204 each had a positive genetic test for
FSHD1 and RB19518 had a negative genetic test for
FSHD1. Subjects 75205 (healthy relative of 75204) and
75195 (healthy relative of 75194) were clinically un-
affected. The FSHD2 family cohort (1090) was previously
described [27] and contains a mutation in the SMCHD1
gene that segregates with disease. Myogenic cells for
cohort 27 were obtained from the previously described
Wellstone Center cell repository housed at the University
of Massachusetts Medical School [6,35].
Sample collection and DNA preparation
Saliva samples (2 mL) were collected from subjects using
the DNAgenotek Oragene Discover (ORG-500) DNA
collection kit and genomic DNAs were isolated using the
manufacturer’s recommended protocol. Genomic DNAs
from blood samples were isolated using the Qiagen Pure-
gene DNA isolation kit using the recommended protocol.
DNA methylation analysis
DNA methylation was analyzed by BSS assay. BS conver-
sion was performed on 1 μg of genomic DNA using the
EpiTect Bisulfite Kit (Qiagen) as per the manufacturer’s
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instructions, and 200 ng of converted genomic DNA
was used per PCR. For the 4qA BSS analysis, converted
DNA was amplified by nested PCR using oligonucleotide
primers and thermocycling conditions that amplify 4qA but
not 4qB; the initial PCR was performed with oligonucleo-
tide primers BSS1438F (5’-GTTTTGTTGGAGGAGTTT
TAGGA) and BSS3742R (5’-AACATTCAACCAAAATTT
CACRAAA) and then followed by nested PCR with
oligonucleotide primers BSS1438F and BSS3626R (5’-
AACAAAAATATACTTTTAACCRCCAAAAA) using 10%
of the first PCR product as template. Polymorphic nucleo-
tide changes that preferentially amplify the 4A subtelomeric
region are underlined. The BSS3742R sequence does not
exist in 4B or 10B and utilizes a polymorphic change at bp
7946 in FJ439133 to eliminate 10A166, and BSS3626R
utilizes polymorphic changes at bp 7827 in FJ439133 to
eliminate 10A, 4B, and 10B [15]. All PCRs were performed
using GoTaq Hot Start Polymerase (Promega) as follows:
94°C for 2 min, 25 cycles of 94°C for 15 sec, 58°C for
20 sec, and 72°C for 50 sec, followed by a final extension
at 72°C for 10 min. The 593-bp PCR product spans the
end of full-length DUX4 exon 1 to the beginning of
DUX4 exon 3, therefore allowing specific analysis of the
methylation status of the most distal 4qA D4Z4 repeat,
which contains 57 CpGs (Additional file 1: Figure S1A).
For the 4qA-L BSS analysis, converted DNA was similarly
amplified by nested PCR. The initial PCR was performed
with oligonucleotide primers BSS4qALF (5’-TTATTTAT
GAAGGGGTGGAGTTTGTT) and BSS3742R, and then
followed by nested PCR with oligonucleotide primers
4qALF and BSS3626R using 10% of the first PCR product
as template. All PCRs were performed using GoTaq Hot
Start Polymerase (Promega) as follows: 94°C for 2 min,
25 cycles of 94°C for 15 sec, 58°C for 20 sec, and 72°C for
30 sec followed by a final extension at 72°C for 10 min.
The 354-bp PCR product spans the 3’ end of the extended
4qA-L D4Z4 repeat to the beginning of DUX4 exon 3,
therefore allowing specific analysis of the methylation
status of the most distal 4qA D4Z4 repeat sequence,
which contains 30 CpGs (Additional file 1: Figure S1D).
When no PCR product was obtained with either the
4qA- or 4qA-L-specific BS PCRs, DNA methylation status
of same distal D4Z4 region was analyzed using primer
BSS3702R (5’-AAAACCAACRAACTCCCTTACAC) in-
stead of BSS3626R. BSS3702R amplifies distal D4Z4 from
both 10A and 4A. For the DUX4 5’ region, BS-converted
DNA was amplified by nested PCR as described above. The
initial PCR was performed with oligonucleotide primers
BSS167F (5’-TTTTGGGTTGGGTGGAGATTTT) and
BSS1036R (5’-AACACCRTACCRAACTTACACCCTT),
and then followed by nested PCR with oligonucleotide
primers BSS475F (5’-TTAGGAGGGAGGGAGGGAGG
TAG) and BSS1036R. A polymorphic nucleotide change at
bp 6748 in FJ439133 (underlined) was used to preferentially
amplify the 4A subtelomeric region. This 578-bp PCR
product contains 61 CpGs to preferentially analyze the
methylation status of the DUX4 5’ region of chromosome
4-type D4Z4 repeats (Additional file 1: Figure S1E).
All BS PCR products were cloned into the pGEM-T
Easy Vector system I (Promega) for sequencing analysis.
At least 10 clones were sequenced for each subject and
their methylation status was analyzed using web-based
analysis software BISMA (http://biochem.jacobs-univer-
sity.de/BDPC/BISMA/) [36] with the default parameters.
Default parameters have a lower threshold of 90% identity
to the reference sequence, a lower threshold of BS conver-
sion rate of 95%, and remove identical sequences derived
from the same genomic template based on conversion
artifacts. To remove PCR amplification bias, 1 CpG in
BSS3626R primer and 2 CpGs in BSS1036R primer were
removed from the analysis; therefore, a total of 56 CpGs,
30 CpGs, and 59 CpGs were analyzed for the 4qA, 4qA-L,
and DUX4 5’ region, respectively. The “R” designation in
primer sequences represents a purine (A or G).
Detection of 10A176T haplotype
BSS analysis using our 4qA-specific BSS primers and
conditions does not amplify 10A176T alleles and will
eliminate 10A176T from analysis. To confirm a 10A176T
haplotype or analyze its DNA methylation status, oligo-
nucleotide primer BSS3626R was replaced with BSS3702R.
The bases corresponding to the 55th CpG in the 4qA BSS
fragment are “TA” in 10A176T alleles due to the G7820A
polymorphic change, and the C7808A polymorphism can
be identified as an “A” instead of a “T” at this position in
the BS-converted 10A176T [15].
Detailed genotyping of 4q chromosomes
Standard genomic PCR was performed on non-converted
DNA to identify the 4qA, 4qA-L, and 4qB chromosomes
as previously described [15].
Additional files
Additional file 1: Figure S1. BSS products. (A) The 4qA BS-converted
PCR product is shown. BSS primer sequences are highlighted in orange
(forward) or blue (reverse). Base pair changes in the BS-converted sequence
between the permissive 4A and non-permissive 4A, 10A, and 10B haplotypes
are highlighted in red (permissive) and yellow (non-permissive). The CpG
dinucleotides that would be missing from the analysis in the designated
haplotypes are identified by number and are underlined. Y = C or T. (B) 4qA
BS PCR primers that have undergone freeze-thaw several times produce minor
PCR products (*), using DNA from cells lacking permissive 4qA alleles. None of
these products correspond to 4qA or 4qB and occasionally correspond to
10qA. (C) Output analysis from BISMA comparing a typical 4qA BSS analysis
with the rare non-permissive 10A166 or 4A166 haplotype BSS outputs that
may appear, as in B, above. These are readily recognized by the absence
of CpGs #16 and 55 (black arrows) and eliminated from analysis. (D) The
4qA-LBS-converted PCR product is shown. BSS primers are highlighted in
orange (forward) or blue (reverse). Base pair changes between 4A-L and
non-permissive 4A and 10A haplotypes are highlighted in red (permissive)
Jones et al. Clinical Epigenetics 2014, 6:23 Page 14 of 16
http://www.clinicalepigeneticsjournal.com/content/6/1/23
and yellow (non-permissive). (E) The DUX4 5’ BS-converted PCR product.
BSS primers are highlighted in orange (forward) or blue (reverse), with the
4q-specific D4Z4 polymorphism in highlighted in red and the 10q D4Z4
polymorphism highlighted in yellow.
Additional file 2: Table S1. BSS assay DNA methylation data.
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